Key result
Carvacrol significantly reduced serum lactate dehydrogenase levels (501.1 vs 756.4, p=0.017) and attenuated severe kidney histopathological damage in rats with isoproterenol-induced myocardial infarction.
Why the study?
Myocardial infarction often causes heart and kidney dysfunction, but the link between heart and kidney damage remains poorly understood, prompting evaluation of the potential protective effect of carvacrol on post-infarction kidney injury.
Does carvacrol prevent kidney injury in a rat model of isoproterenol-induced myocardial infarction?
Does carvacrol prevent kidney injury in a rat model of isoproterenol-induced myocardial infarction?
Absolute Event Rate: 501.1% vs 756.4%
p-value: p=0.017
Carvacrol demonstrated protective effects against kidney injury and reduced myocardial injury markers in a rat model of isoproterenol-induced myocardial infarction.
Hypothesis-generating for carvacrol renoprotection in MI; should not yet change practice.
BACKGROUND: Myocardial infarction is a major cause of morbidity and mortality, often leading to heart and kidney dysfunction. Despite advancements in treatment, the link between heart and kidney damage is poorly understood. This study aims to evaluate the potential protective effect of Carvacrol, a natural bioactive compound, on kidney injury induced by myocardial infarction. METHODS: In this experimental study, 32 male Wistar rats were divided into four groups: Control, Carvacrol (50 mg/kg), Myocardial Infarction (85 mg/kg isoproterenol), and Myocardial Infarction + Carvacrol (50 mg/kg Carvacrol + 85 mg/kg isoproterenol). Carvacrol was administered for six weeks, and myocardial infarction was induced with isoproterenol. Blood pressure, biochemical parametres (creatinin kinase, lactate dehydrogenase, urea, creatinine, GDF-15, IL-6), and kidney tissue histopathology were evaluated. RESULTS: Biochemical analysis showed increased Creatinin Kinase and Lactate Dehydrogenase levels in the Myocardial Infarction group compared to controls(p = 0.023, p = 0.020), with carvacrol reducing these markers. IL-6 and GDF-15 levels were elevated in both the Myocardial Infarction and Myocardial Infarction + Carvacrol groups (p = 0.009, p < 0.001). Blood pressure was significantly reduced in the Myocardial Infarction group. Histopathological examination revealed severe kidney damage in the Myocardial Infarction group, while Carvacrol treatment showed less kidney damage, with only mild tubular dilation and rare necrosis. CONCLUSION: Carvacrol appears to have protective effects against kidney injury in myocardial infarction. It reduced myocardial injury markers and kidney damage, suggesting its potential therapeutic use in cardiorenal syndrome. Further studies are needed to understand its mechanisms and clinical applications in cardiovascular and renal diseases.
No takes yet. Share an insight, caveat, or question.
Ünlü et al. (2025) studied Isoproterenol-induced myocardial infarction and kidney injury (n=32). Carvacrol vs. Isoproterenol-induced myocardial infarction without carvacrol was evaluated on Serum Lactate Dehydrogenase (LDH) levels (p=0.017). Carvacrol significantly reduced serum lactate dehydrogenase levels (501.1 vs 756.4, p=0.017) and attenuated severe kidney histopathological damage in rats with isoproterenol-induced myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: